Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
19 studies found for:    acc-001
Show Display Options
RSS Create an RSS feed from your search for:
acc-001
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: ACC-001 (vanutide cridificar)
2 Completed Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: ACC-001 3 μg/ QS-21 50 μg;   Biological: ACC-001 10 μg/ QS-21 50 μg;   Other: Placebo- Phosphate buffered saline (PBS)
3 Completed Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001 + QS-21;   Biological: ACC-001;   Biological: QS-21;   Drug: Placebo: Phosphate buffered saline
4 Completed Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001 + QS-21;   Biological: QS-21;   Other: Diluent: Phosphate Buffered Saline;   Biological: ACC-001
5 Completed Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001;   Other: QS-21;   Other: PBS
6 Completed Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: ACC-001+ QS21;   Drug: ACC-001;   Drug: ACC-001 + QS21
7 Terminated Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: ACC-001
8 Completed A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: ACC-001+ QS21
9 Completed Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: ACC-001;   Other: QS-21
10 Completed Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"
Condition: Dietary Carcinogenesis
Interventions: Drug: ACCS100;   Drug: Placebo
11 Recruiting A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Conditions: Cancer;   Neuroendocrine Tumors;   NET;   Adrenocortical Carcinoma;   ACC
Intervention: Drug: TKM-080301
12 Completed
Has Results
Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose
Conditions: Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Interventions: Device: BD/33G;   Device: OTM / 33G;   Device: OTU/28G;   Device: ACC/28G;   Device: OTM/28G
13 Recruiting Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Conditions: Adrenocortical Carcinoma;   Adrenal Cancer;   ACC
Intervention: Drug: ATR-101
14 Completed Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
Condition: Uveitis, Anterior
Interventions: Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System;   Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System;   Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System;   Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
15 Completed Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
Condition: Carcinoma, Adrenal Cortical
Interventions: Drug: Etoposide;   Drug: Doxorubicin;   Drug: Cisplatin;   Drug: Streptozotocin;   Drug: Mitotane
16 Unknown  Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment
Condition: HIV Infections
Interventions: Drug: lamivudine, abacavir , ritonavir, atazanavir;   Drug: emtricitabine, tenofovir, ritonavir, atazanavir
17 Terminated CyberKnife® for Hepatic Metastases From Colorectal Cancer
Condition: Colorectal Liver Metastases
Intervention: Radiation: CyberKnife SBRT
18 Completed Growth and Safety of a Low Lactose Milk-Based Infant Formula
Conditions: Growth;   Healthy Term Infants
Intervention: Other: Low Lactose Infant Formula
19 Recruiting MSB0010718C in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: MSB0010718C

Indicates status has not been verified in more than two years